Herpesvirus Saimiri DNA Detection and Antiviral Therapy for IPF
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for idiopathic pulmonary fibrosis (IPF) are ineffective due to the unknown cause of the disease, and existing antiviral treatments have shown mixed results, with no effective method to diagnose or monitor HVS infection-associated diseases.
Innovation Solution
Developing methods to detect Herpesvirus saimiri DNA in clinical samples using labeled nucleic acid probes and amplification techniques, and administering agents that inhibit virus replication or down-regulate virus-specific proteins to treat viral diseases like IPF and associated cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for idiopathic pulmonary fibrosis are used, then treatment is provided, but the therapies are ineffective due to unknown cause
Solution Approach 1:
The patent applies preliminary action by developing diagnostic methods to detect HVS infection before initiating treatment. The invention enables identification of the viral cause through nucleic acid detection in clinical samples, allowing targeted antiviral therapy to be administered prior to disease progression, thereby resolving the effectiveness problem caused by unknown etiology
2Reliability
If existing antiviral treatments are administered, then virus infection is targeted, but results are mixed with no effective diagnostic or monitoring method
Solution Approach 1:
The patent implements feedback by establishing a diagnostic monitoring system using labeled nucleic acid probes to detect HVS DNA in clinical samples. This enables continuous monitoring of viral infection status and treatment response, providing feedback information that allows clinicians to adjust therapy and improve overall treatment efficacy
Solution Approach 2:
The patent uses labeled nucleic acid probes as intermediaries to detect and monitor HVS infection. These probes serve as mediators between the viral genetic material and the diagnostic system, enabling accurate detection and monitoring without directly interfering with the virus or treatment mechanisms
3Measurement precision
If methods to detect HVS DNA are developed, then accurate diagnosis is enabled, but detection sensitivity and specificity must be optimized
Solution Approach 1:
The patent applies local quality by designing nucleic acid probes with specific sequences that target unique regions of HVS DNA. This localized specificity ensures that only the intended viral target is detected, enhancing diagnostic accuracy by distinguishing HVS from other viruses and reducing false positive results
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed methods enable accurate diagnosis and monitoring of HVS infection-associated diseases and provide therapeutic options to inhibit virus replication, potentially halting or reversing disease progression in IPF and other conditions.
Implementation Method 1
detecting the presence of a virus-specific element from a virus in a clinical sample
Implementation Method 2
amplification techniques
Implementation Method 3
agents that inhibit virus replication or down-regulate virus-specific proteins
Data Source
AI summary
Provided are methods of diagnosing a viral disease such as idiopathic pulmonary fibrosis, Castleman's disease, a lymphoma, a thymoma or a sarcoma in a patient by identifying one or more virus-specific elements such as a nucleic acid or a viral protein or a patient antibody to a virus-specific element, as well as to kits for diagnosing the viral disease in a patient. Further provided are methods of monitoring disease progression and/or the efficacy of therapy by measuring the levels of a virus-specific element in a sample from a patient, and methods of identifying therapeutic agents that show efficacy in reducing levels of virus-specific agents in vitro. Still further provided are methods of treating idiopathic pulmonary fibrosis, a lymphoproliferative disease and cancer, as well as to methods of preventing viral infection, including Herpesvirus saimiri infection.